Evidence map›Paper›PMID 42514213›Full record

ArticleLife (Basel, Switzerland)2026

Clinical Safety and Performance of Ultra-High Dk Tisilfocon A Orthokeratology Lenses: A Prospective Multicenter Study.

Shang-Yen Wu, Jen-Hung Wang, Ti-Yen Cheng, Cheng-Jen Chiu

Abstract read
In one paragraph

Article in Life (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Shang-Yen WuDepartment of Ophthalmology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien 970, Taiwan.
Jen-Hung WangDepartment of Medical Research, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien 970, Taiwan.ORCID 0000-0002-4946-8064
Ti-Yen ChengSchool of Medicine, Tzu Chi University, Hualien 970, Taiwan.
Cheng-Jen ChiuDepartment of Ophthalmology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien 970, Taiwan.ORCID 0000-0002-4004-5823

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This prospective multicenter study evaluated the safety and clinical performance of ultra-high Dk (180 ISO/Fatt) Tisilfocon A orthokeratology (Ortho-K) lenses to treat myopia. We enrolled 67 participants aged 8-49 years with myopia up to 8.00 D. Participants were followed for 36 weeks to assess uncorrected visual acuity (UCVA), axial length (AL), and corneal endothelial cell density (ECD). From the first week, UCVA significantly improved and remained stable through week 36. AL elongation was statistically significant overall, driven primarily by age-appropriate physiological growth in younger participants; adults and individuals with high myopia showed no significant axial elongation. Safety evaluations showed high biocompatibility with no adverse events exceeding Grade 2 corneal staining. ECD remained stable after 36 weeks of lens wear, demonstrating that the ultra-high oxygen permeability of Tisilfocon A supports corneal health and prevents hypoxic stress during overnight wear. Overall, these findings suggest that ultra-high Dk Tisilfocon A Ortho-K lenses are a safe and effective clinical solution for myopia management across diverse patients, providing long-term corneal integrity and stable visual outcomes. ECD remained stable over the 36-week observation period, providing reassuring short- to mid-term evidence that the ultra-high oxygen permeability of Tisilfocon A may help limit hypoxic stress during overnight wear. Overall, these findings suggest that ultra-high Dk Tisilfocon A Ortho-K lenses are well tolerated and clinically effective across diverse patients during this period; however, in the absence of a concurrent control group and given the relatively short follow-up, these results should be regarded as preliminary, and longer-term controlled studies are needed to confirm the durability of axial length control and corneal endothelial safety.

Indexed as

myopiaorthokeratology (Ortho-K)prospective multicenter studyultra-high Dk Tisilfocon A

Identifiers

PMID42514213
PMCPMC13412474

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.